Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

2 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A

2(40.0%)

Phase 2

1(20.0%)

Phase 3

1(20.0%)

Phase 4

1(20.0%)

5Total

N/A(2)

Phase 2(1)

Phase 3(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT07412483Not ApplicableRecruiting

A Controlled Human Infection Model of Dengue

Role: collaborator

NCT07411638Not Yet Recruiting

Non-interventional Translational Study in Mild, Moderate and Severe Acne Patients

Role: collaborator

NCT06654973Not ApplicableActive Not Recruiting

Singapore SARS-CoV-2 Human Challenge Study

Role: collaborator

NCT05479370Phase 3Completed

Immunogenicity Trial of 3 Influenza Vaccines

Role: collaborator

NCT05142319Phase 4Completed

Efficacy of Different COVID-19 Vaccine Combinations in Inducing Long-term Humoral Immunity [PRIBIVAC]

Role: collaborator

NCT03670342Completed

Pilot Study of Somatostatin Receptor Imaging in Nasopharyngeal Cancer

Role: collaborator

NCT02544490Completed

Defining Circulating Micro-RNA Biomarkers for the Early Diagnosis and Prognosis of Sepsis

Role: collaborator

NCT02774993Phase 2Completed

Doxycycline in Human Pulmonary Tuberculosis

Role: collaborator

All 8 trials loaded